Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Nicola S. Meagher(The University of Sydney), Kayla Klett(University of California, Los Angeles), Angela Chou(Royal North Shore Hospital), Jennifer Alsop(Manchester Academic Health Science Centre), Derek S. Chiu(University of British Columbia), Charlie Gourley(Edinburgh Cancer Research), Anusha Hettiaratchi(UNSW Sydney), Rhonda Farrell(Prince of Wales Hospital), Esther Elishaev(University of Pittsburgh), Kylie L. Gorringe(The University of Melbourne), Claus Høgdall(Copenhagen University Hospital), Kara L. Cushing‐Haugen(Fred Hutch Cancer Center), David D.L. Bowtell(The University of Melbourne), Adelyn Bolithon(Cancer Institute of New South Wales), Tomasz Huzarski(International Hereditary Cancer Center), Michael S. Anglesio(University of British Columbia), Kylie‐Ann Mallitt(The University of Sydney), C. Blake Gilks(Vancouver General Hospital), Anthony J. Gill(The University of Sydney), Ian Campbell(The University of Sydney), Andrew Berchuck(General Marble (Greece)), Ellen Barlow(Royal Hospital for Women), Matthias W. Beckmann(Universitätsklinikum Erlangen), Jae‐Weon Kim(Seoul National University), Arndt Hartmann(Universitätsklinikum Erlangen), Catherine J. Kennedy(The University of Sydney), Joshua G. Cohen(University of California, Los Angeles), James D. Brenton(Cambridge University Hospitals NHS Foundation Trust), Zhuxuan Fu(Saint Luke's Health System), Anna Fischer(University of Tübingen), Anna Jakubowska(Pomeranian Medical University), Byoung‐Gie Kim(Samsung Medical Center), Adeline Tan(Albert Einstein College of Medicine), Jessica Boros(The University of Sydney), Holly R. Harris(Fred Hutch Cancer Center), Joellen M. Schildkraut(Duke University Hospital), Dane Cheasley(The University of Melbourne), Marcel Grube(University of British Columbia), Chi Nam Ignatius Pang(UNSW Sydney), Paul R. Harnett(The University of Sydney), Jennifer A. Doherty(Cancer Prevention Institute of California), Alison H. Brand(The University of Sydney), Ksenia Chezar(University of Toronto), Cezary Cybulski(International Hereditary Cancer Center), Ramona Erber(Friedrich-Alexander-Universität Erlangen-Nürnberg), Matthew J. Wakefield(The University of Melbourne), Jae‐Hoon Kim(Bio-Medical Science (South Korea)), Mercedes Jimenez‐Liñan(University of Kansas)
Cited by 22
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k